Last reviewed · How we verify

LYN-005 — Competitive Intelligence Brief

LYN-005 (LYN-005) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Drug delivery platform / Gastric-resident capsule. Area: Drug Delivery Technology.

phase 3 Drug delivery platform / Gastric-resident capsule Drug Delivery Technology Small molecule Live · refreshed every 30 min

Target snapshot

LYN-005 (LYN-005) — Lyndra Inc.. LYN-005 is a gastric-resident capsule designed to deliver oral medications in a controlled, prolonged manner within the stomach.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LYN-005 TARGET LYN-005 Lyndra Inc. phase 3 Drug delivery platform / Gastric-resident capsule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Drug delivery platform / Gastric-resident capsule class)

  1. Lyndra Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LYN-005 — Competitive Intelligence Brief. https://druglandscape.com/ci/lyn-005. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: